

REPORT

On the results of share issuance for 2025 dividend payment

To: State Securities Commission

I. Information on the Issuer

1. Full name of the Issuer: Agimexpharm Pharmaceutical Joint Stock Company
2. Abbreviated name: AGIMEXPHARM
3. Head office address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam
4. Telephone: (+84) 296 3856961 – 3856964 Fax: (+84) 296 3857301
Website: www.agimexpharm.com
5. Charter capital: VND 306,075,580,000
6. Stock code: AGP
7. Bank account: Vietnam Joint Stock Commercial Bank for Industry and Trade (VietinBank) – An Giang Branch
Account No.: 110000016076
8. Enterprise Registration Certificate: Enterprise Code No. 1600699279 issued for the first time by the Department of Planning and Investment of An Giang Province on June 3, 2004, the 21st amendment issued by the Department of Finance of An Giang Province on January 27, 2026
 - Primary business line: Manufacture of pharmaceuticals, medicinal chemicals and botanical products
 - Business code: 2100
 - Main products/services: Pharmaceutical and medicinal products
9. Establishment and operation license (if any as required by specialized laws): Certificate of eligibility for pharmaceutical business No. 4526/DKKDD-AG. 3rd issuance: Certificate No. 4133/DKKDD-AG dated December 20, 2023.

II. Issuance plan

1. Name of share: Shares of Agimexpharm Pharmaceutical Joint Stock Company
2. Share type: Common shares
3. Number of shares prior to the issuance:
 - Total number of issued shares: 30,607,558 shares
 - Total number of outstanding shares: 30,607,558 shares
 - Total number of treasury shares: 0 share
4. Estimated number of shares to be issued: 3,672,906 shares

5. Subscription ratio: 25:03. For every 1 share owned, a shareholder will receive 1 right to subscribe for additional shares. Every 25 rights will entitle the shareholder to 3 additional new shares

6. Source of capital: Retained earnings after tax as of December 31, 2025, based on the audited financial statements for the year 2025 of Agimexpharm Pharmaceutical Joint Stock Company

7. Plan to handle the fractional shares: The number of additional shares issued to each shareholder will be rounded down to the nearest whole number, and any fractional shares (if any) will be canceled.

*For example: Shareholder A owns 122 shares as of the record date. With a subscription ratio of 25:03, Shareholder A is entitled to receive $(122 * 3 / 25) = 14.64$ new shares. Following this calculation method, Shareholder A will receive 14 additional shares, and the fractional portion of 0.64 shares will be canceled.*

The difference between the total projected amount for issuing shares to pay dividends (calculated at a par value of VND 10,000 per share) and the total value of shares actually distributed to existing shareholders (calculated at a par value of VND 10,000 per share) will be allocated to the Company's Development Investment Fund.

8. End date of the issuance: May 29, 2026

9. Expected date of share transfer: From June 2026 to July 2026.

III. Results of share issuance

1. Number of shares distributed: 3,672,486 shares, of which:

- Shares distributed to shareholders according to the entitlement ratio: 3,672,486 shares to 911 shareholders;
- Shares arising from the treatment of fractional entitlements: 420 shares (cancelled).

2. Number of shares after the issuance (as of June 10, 2026): 35,810,421 shares, of which:

- Number of outstanding shares: 35,810,421 shares (*);
- Number of treasury shares: 0 share.

(*) Notes:

Number of outstanding shares: 35,810,421 shares, including:

- *Shares prior to issuance: 30,607,558 shares;*
- *Shares issued for dividend payment in 2025 (on May 29, 2026): 3,672,486 shares;*
- *Shares issued under the Employee Stock Ownership Plan (on June 8, 2026): 1,530,377 shares.*

IV. Attached documents

Notice of change in the number of voting shares.

An Giang, June 10, 2026

AGIMEXPHARM PHARMACEUTICAL JSC
GENERAL DIRECTOR



REPORT

On the results of share issuance under the Employee Stock Ownership Plan

To: State Securities Commission

I. Information on the Issuer

1. Full name of the Issuer: Agimexpharm Pharmaceutical Joint Stock Company
2. Abbreviated name: AGIMEXPHARM
3. Head office address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam
4. Telephone: (+84) 296 3856961 – 3856964 Fax: (+84) 296 3857301
Website: www.agimexpharm.com
5. Charter capital: VND 306,075,580,000
6. Stock code: AGP
7. Bank account: Vietnam Joint Stock Commercial Bank for Industry and Trade (VietinBank) – An Giang Branch
Account No.: 110000016076
8. Enterprise Registration Certificate: Enterprise Code No. 1600699279 issued for the first time by the Department of Planning and Investment of An Giang Province on June 3, 2004, the 21st amendment issued by the Department of Finance of An Giang Province on January 27, 2026
 - Primary business line: Manufacture of pharmaceuticals, medicinal chemicals and botanical products
 - Business code: 2100
 - Main products/services: Pharmaceutical and medicinal products
9. Establishment and operation license (if any as required by specialized laws): Certificate of eligibility for pharmaceutical business No. 4526/DKKDD-AG. 3rd issuance: Certificate No. 4133/DKKDD-AG dated December 20, 2023.

II. Issuance plan

1. Name of share: Shares of Agimexpharm Pharmaceutical Joint Stock Company
2. Share type: Common shares
3. Number of shares prior to the issuance:
 - Total number of issued shares: 30,607,558 shares
 - Total number of outstanding shares: 30,607,558 shares
 - Total number of treasury shares: 0 share
4. Estimated number of shares to be issued: 1,530,377 shares, equivalent to 5% of total outstanding shares.

5. Transfer restriction: ESOP shares shall be restricted from transfer for 01 year from the completion date of the issuance.

6. Issuance price: VND 18,000/share

7. Source of capital: None

8. End date of the issuance: June 08, 2026

9. Expected date of share transfer: From June 2026 to July 2026.

III. Results of share issuance

1. Number of shares distributed: 1,530,377 shares, equivalent to 100% of the total shares offered.

2. Number of employees allocated shares: 297 employees.

3. Total number of shares after the issuance (as of June 10, 2026): 35,810,421 shares, of which:

- Outstanding shares: 35,810,421 shares
- Treasury shares: 0 share.

(* Notes:

Number of outstanding shares: 35,810,421 shares, including:

- *Shares prior to issuance: 30,607,558 shares;*
- *Shares issued for dividend payment in 2025 (on May 29, 2026): 3,672,486 shares;*
- *Shares issued under the Employee Stock Ownership Plan (on June 8, 2026): 1,530,377 shares.*

IV. Attached documents

1. Minutes of the Board of Directors' Meeting No. 09/BB-AGP.HDQT dated June 5, 2026;

2. Resolution of the Board of Directors No. 12/NQ-AGP.HDQT dated June 5, 2026 on approval of the plan to handle unsubscribed shares under the Employee Stock Ownership Plan (ESOP);

3. List of employees and number of shares reallocated under the ESOP;

4. Minutes of the Board of Directors' Meeting No. 10/BB-AGP.HDQT dated June 9, 2026;

5. Resolution of the Board of Directors No. 13/NQ-AGP.HDQT dated June 9, 2026 on approval of the results of employees' subscription and payment for shares under the Employee Stock Ownership Plan (ESOP);

6. List of employees participating in the Employee Stock Ownership Plan (ESOP) share issuance;

7. Confirmation letter from Vietnam Joint Stock Commercial Bank for Industry and Trade – An Giang Branch regarding the proceeds collected from the ESOP issuance (together with authorization letter of the signatory);

8. Change in number of shares with voting rights.

An Giang, June 10, 2026

**AGIMEXPHARM PHARMACEUTICAL JSC
GENERAL DIRECTOR**


NGUYEN VAN KHA